Abstract:Background & aims: Cirrhosis-associated immune dysfunction (CAID) affects both innate and adaptive immunity. This study investigated the complement system, immunoglobulins, and acute-phase proteins and their prognostic relevance in patients with advanced chronic liver disease (ACLD). Methods: Patients with ACLD (hepatic venous pressure gradient [HVPG] ≥6 mmHg) but without acute decompensation/infections were characterised by HVPG and by clinical EASL stages: compensated (cACLD; S0-2) vs. decompensated ACLD (dACLD) with previous variceal bleeding (S3), non-bleeding decompensation (S4), or further decompensation (S5). Complement factors (C3c, C4, CH50), immunoglobulins (IgA, IgM, IgG, IgG1-4), acute-phase proteins and systemic inflammation biomarkers (white blood cells, C-reactive protein, IL-6, procalcitonin) were measured. Results: A total of 245 patients (median model for end-stage liver disease score: 11 [9-15], median HVPG: 17 [12-21] mmHg) were included with 150 (61%) presenting dACLD. Complement levels and activity significantly decreased in dACLD substages S4 and S5 (p <0.001). Total IgA/IgM/IgG and IgG1-4 subtype levels increased in patients with dACLD (all p <0.05). Complement and immunoglobulin levels correlated negatively and positively, respectively, with systemic inflammation (all p <0.05). High IgG-1 (adjusted hazard ratio per 100 mg/dl: 1.12, 1.04-1.19, p = 0.002) and IL-6 (adjusted hazard ratio: 1.03, 1.00-1.05, p = 0.023) levels predicted the development of infections during follow-up. High IgA (stratified by median; log-rank p <0.001), high IgG1 (log-rank p = 0.043) and low C3c (log-rank p = 0.003) indicated a higher risk of first/further decompensation or liver-related death (composite endpoint). Next to HVPG and IL-6, low C3c (adjusted hazard ratio per mg/dl: 0.99, 0.97-0.99, p = 0.040) remained independently associated with the composite endpoint on multivariate Cox regression analysis. Conclusions: Complement levels and immunoglobulins may serve as surrogates of cirrhosis-associated immune dysfunction and associate with cirrhosis severity and systemic inflammation. Low complement C3c predicted decompensation and liver-related death, whereas high IgG-1 indicated an increased risk for infections. Impact and implications: Patients with cirrhosis are at increased risk for infections, which worsen their prognosis. We found a significant dysregulation of several essential components of the immune system that was linked to disease severity and indicated a risk for infections and other complications. Simple blood tests identify patients at particularly high risk, who may be candidates for preventive measures. Clinical trials registration: This study is registered at ClinicalTrials.gov (NCT03267615).

Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure

Association of ABO blood types with VWF, FⅧ and ADAMTS13 levels and disease severity in liver cirrhosis patients

Circulating Proteomic Panels For Diagnosis And Risk Stratification Of Acute-On-Chronic Liver Failure In Patients With Viral Hepatitis B

Assessment and management of coagulopathy in critically-ill patients with liver failure

Altered clot formation and lysis are associated with increased fibrinolytic activity in ascites in patients with advanced cirrhosis

[Coagulation disorders in liver cirrhosis - Diagnostics and management]

Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference

Whole blood thrombin generation improves the understanding of cirrhotic coagulopathy and predicts clinical outcomes in patients with cirrhosis: a prospective cohort study

Hematological ratios in patients with acute decompensation and acute-on-chronic liver failure: prognostic factors

Cirrhosis Progression Is Not Associated with Clinically Significant Alterations in Global Hemostasis Assessed by Thromboelastography

P5405Clinical and prognostic relevance of increased liver stiffness coupled with abnormal liver function tests in decompensated heart failure

Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences

Acute decompensation of cirrhosis versus acute‐on‐chronic liver failure: What are the clinical implications?

Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers

Whole blood thrombin generation shows a significant hypocoagulable state in patients with decompensated cirrhosis

Liver Dysfunction and Systemic Inflammation Drive Organ Failures in Acute Decompensation of Cirrhosis: A Multi-Centric Study

Coagulation profile and platelet function in patients with extrahepatic portal vein obstruction and non-cirrhotic portal fibrosis

Coagulation disorders in patients with severe hemophagocytic lymphohistiocytosis

Dysregulated biomarkers of innate and adaptive immunity predict infections and disease progression in cirrhosis

Acute-on-chronic liver failure: far to go—a review

Hepatic and extrahepatic metabolic modulation in hbv-related decompensated cirrhosis and acute-on-chronic liver failure